Literature DB >> 27195751

The Diagnostic Challenge of Group 2 Pulmonary Hypertension.

Robert Naeije1, Michele D'Alto2.   

Abstract

Pulmonary hypertension (PH) secondary to left heart diseases associated with an increased pulmonary venous pressure is the second of a total of five groups recognized in the classification of PH. Group 2 PH is the commonest form of PH, and is associated with high morbidity and mortality. The diagnosis of group 2 PH relies on a clinical probability assessment in which echocardiography plays a major role, eventually followed by the invasive measurements of a mean pulmonary artery pressure (mPAP) ≥25mmHg and a wedged PAP (PAWP) >15mmHg. This combination of mPAP and PAWP defines "post-capillary PH" (pcPH). Post-capillary PH is most often associated with a diastolic pressure gradient (DPG) or gradient between diastolic PAP and PAWP <7mmHg and/or a pulmonary vascular resistance (PVR) ≤3Wood units (WU), and is called isolated pcPH (IpcPH). Postcapillary PH with a DPG ≥7mmHg and/or a PVR >3WU is then combined pre- and postcapillary PH (CpcPH). Post-capillary PH is associated with a decreased survival in proportion to increased PAP and decreased right ventricular (RV) ejection fraction. CpcPH occurs in 12-13% of patients with pcPH. CpcPH is associated with pulmonary vascular remodeling and altered RV-arterial coupling. The prognosis of CpcPH is poor.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diastolic pressure gradient; Echocardiography; Heart failure; Postcapillary pulmonary hypertension; Pulmonary hypertension; Pulmonary vascular resistance; Transpulmonary pressure gradient

Mesh:

Year:  2016        PMID: 27195751     DOI: 10.1016/j.pcad.2016.05.003

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  8 in total

Review 1.  Pulmonary Hypertension in Heart Failure Patients: Pathophysiology and Prognostic Implications.

Authors:  Marco Guazzi; Valentina Labate
Journal:  Curr Heart Fail Rep       Date:  2016-12

Review 2.  Combined pre- and post-capillary pulmonary hypertension in left heart disease.

Authors:  M Riccardi; M Pagnesi; E Sciatti; C M Lombardi; R M Inciardi; M Metra; E Vizzardi
Journal:  Heart Fail Rev       Date:  2022-06-01       Impact factor: 4.214

3.  Comparison of PCWP and LVEDP Measurements in Patients with Severe Aortic Stenosis Undergoing TAVI-Same Same but Different?

Authors:  Elke Boxhammer; Moritz Mirna; Laura Bäz; Brunilda Alushi; Marcus Franz; Daniel Kretzschmar; Uta C Hoppe; Alexander Lauten; Michael Lichtenauer
Journal:  J Clin Med       Date:  2022-05-25       Impact factor: 4.964

Review 4.  Pulmonary Vascular Disease: Hemodynamic Assessment and Treatment Selection-Focus on Group II Pulmonary Hypertension.

Authors:  Bhavadharini Ramu; Brian A Houston; Ryan J Tedford
Journal:  Curr Heart Fail Rep       Date:  2018-04

5.  Clinical and hemodynamic factors in predicting response to fluid challenge during right heart catheterization.

Authors:  Nima Moghaddam; John R Swiston; Robert D Levy; Lisa Lee; Victor F Huckell; Nathan W Brunner
Journal:  Pulm Circ       Date:  2018-12-03       Impact factor: 3.017

6.  Transition from post-capillary pulmonary hypertension to combined pre- and post-capillary pulmonary hypertension in swine: a key role for endothelin.

Authors:  Richard W B van Duin; Kelly Stam; Zongye Cai; André Uitterdijk; Ana Garcia-Alvarez; Borja Ibanez; A H Jan Danser; Irwin K M Reiss; Dirk J Duncker; Daphne Merkus
Journal:  J Physiol       Date:  2018-06-21       Impact factor: 5.182

7.  Fatty acid-binding protein 5 aggravates pulmonary artery fibrosis in pulmonary hypertension secondary to left heart disease via activating wnt/β-catenin pathway.

Authors:  Qian Lei; Zhimin Yu; Hang Li; Jun Cheng; Yanggan Wang
Journal:  J Adv Res       Date:  2021-11-26       Impact factor: 12.822

8.  Practice patterns of pulmonary hypertension secondary to left heart disease among pediatric pulmonary hypertension providers.

Authors:  Hythem Nawaytou; Jeffrey R Fineman; Shahin Moledina; Dunbar Ivy; Steven H Abman; Maria J Del Cerro
Journal:  Pulm Circ       Date:  2021-02-09       Impact factor: 3.017

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.